Nemtabrutinib

Small molecule

Also known as MK-1026

Phase 3Mechanism not established
Phase 3underway

Evidence outlook · registrational

Chronic Lymphocytic Leukemia: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2027-05-19.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Chronic Lymphocytic Leukemia
NCT05947851 · Merck Sharp & Dohme LLC
2023-08-08 – 2035-07-01 · Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma, Lymphoma, Small Lymphocytic, CLL, SLL
What this study did
NCT06136559 · Merck Sharp & Dohme LLC
2023-12-13 – 2032-09-07 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT05624554 · Merck Sharp & Dohme LLC
2023-03-16 – 2031-03-17 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
Phase 2 (11)
Chronic Lymphocytic Leukemia
NCT07796373 · National Heart, Lung, and Blood Institute (NHLBI)
2026-11-24 – 2031-12-01 · Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
What this study did
NCT07690891 · Medical College of Wisconsin
2026-10-01 – 2031-09-01 · Chronic Lymphocytic Leukemia
What this study did
NCT06863402 · Roswell Park Cancer Institute
2026-11-15 – 2030-06-01 · Richter Syndrome, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia
What this study did
NCT07194980 · Fred Hutchinson Cancer Center
2026-12-01 – 2029-10-20 · Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
What this study did
NCT05458297 · Merck Sharp & Dohme LLC
2022-07-21 – 2029-05-17 · Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
What this study did
NCT07557056 · Jennifer Woyach
2026-11-01 – 2027-12-31 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
Other / comorbidity
NCT07673367 · Vanderbilt-Ingram Cancer Center
2026-07-31 – 2032-07-31 · Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
What this study did
NCT07583810 · City of Hope Medical Center
2026-10-23 – 2030-09-25 · Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma, Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Lymphoma, Extranodal Marginal Zone Lymphoma
What this study did
NCT07464210 · Seoul National University Hospital
2026-06-01 – 2030-08-01 · Waldenstrom Macroglobulinemia
What this study did
NCT04728893 · Merck Sharp & Dohme LLC
2021-04-05 – 2029-01-04 · Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
What this study did
NCT06572618 · City of Hope Medical Center
2025-01-22 – 2027-01-08 · Mantle Cell Lymphoma
What this study did
Phase 1/2 (1)
Chronic Lymphocytic Leukemia
NCT03162536 · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
2017-06-26 – 2027-09-17 · Lymphoma, B-Cell, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Richter's Transformation, Follicular Lymphoma, Marginal Zone Lymphoma
What this study did
Phase 1 (11)
Other / comorbidity
NCT05347225 · Merck Sharp & Dohme LLC
2022-06-09 – 2028-12-29 · Hematological Malignancies
What this study did
NCT07734610 · Merck Sharp & Dohme LLC
2026-09-08 – 2027-02-01 · Severe Renal Impairment, Healthy
What this study did
NCT06442436 · Merck Sharp & Dohme LLC
2024-07-24 – 2026-08-13 · Hepatic Impairment (HI)
What this study did
NCT07232589 · Merck Sharp & Dohme LLC
2025-12-08 – 2026-06-17 · Healthy
What this study did
NCT05673460 · Merck Sharp & Dohme LLC
2023-02-13 – 2025-09-03 · Mature B-cell Neoplasms
What this study did
NCT06772818 · Merck Sharp & Dohme LLC
2023-10-02 – 2024-02-16 · Healthy
What this study did
NCT06625827 · Merck Sharp & Dohme LLC
2023-11-07 – 2024-01-22 · Healthy
What this study did
NCT06688045 · Merck Sharp & Dohme LLC
2023-10-30 – 2024-01-06 · Healthy
What this study did
NCT06772805 · Merck Sharp & Dohme LLC
2023-07-24 – 2023-12-12 · Healthy
What this study did
NCT06586671 · Merck Sharp & Dohme LLC
2023-08-28 – 2023-11-13 · Hematological Malignancy
What this study did
NCT06698016 · Merck Sharp & Dohme LLC
2023-07-25 – 2023-10-30 · Healthy
What this study did

Competitive landscape

This drug's own stage for Chronic Lymphocytic Leukemia: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Nemtabrutinib: this drugPhase 3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
AcalabrutinibApprovedSmall moleculeBTKPartial signalFeatured results are non-efficacy only in this race
AlemtuzumabApprovedMonoclonal antibodyCD52not yet gradedNo reviewed efficacy summary in this indication
IbrutinibApprovedSmall moleculeBTKPartial signal
NCT01611090: Progression-free Survival (PFS) (Up to 5 years): Ibrutinib+BR 65.12 Months | Placebo+BR 14.32 Months (95% CI 13.86 to 16.62)
ObinutuzumabApprovedMonoclonal antibodyCD20Partial signalNo reviewed efficacy summary in this indication
PF-05280586ApprovedBiologic (subtype unspecified)CD20not yet gradedNo reviewed efficacy summary in this indication
PirtobrutinibApprovedSmall moleculeBTKPartial signalFeatured results are non-efficacy only in this race
Rituximab (Rituxan)ApprovedMonoclonal antibodyCD20, CD20-directed Cytolytic Antibodynot yet gradedNo reviewed efficacy summary in this indication
Rituximab-Abbs (Truxima)ApprovedMonoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
VenetoclaxApprovedSmall moleculeBCL-2Partial signal
NCT02005471: Investigator-assessed PFS, venetoclax-rituximab vs bendamustine-rituximab: 2-year rates 84.9% vs 36.3% (hazard ratio 0.17; P<0.001)
Zanubrutinib (Brukinsa)ApprovedSmall moleculeBTKPartial signal
NCT03734016: Overall response rate, zanubrutinib (n=327) vs ibrutinib (n=325): by independent review 86.2% vs 75.7%, response ratio 1.14 (95% CI 1.05 to 1.22), non-inferiority p<0.0001, superiority p=0.0007; by investigator 83.5% vs 74.2%, response ratio 1.12 (95% CI 1.04 to 1.22), non-inferiority p<0.0001, superiority p=0.0035 (CT.gov posted results).
BexobrutidegPhase 3Small moleculeBruton's tyrosine kinase (BTK)not yet gradedNo reviewed efficacy summary in this indication
Sonrotoclax (Beqalzi)Phase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MesutoclaxPhase 2/3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MS-553Phase 1/2Small moleculeProtein kinase C-beta (PKC-beta)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(17 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Nemtabrutinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (6)
January 2027 (1)
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2027-01-08 · NCT06572618 · CT.gov ↗
What to watch
February 2027 (1)
Phase 1Severe Renal Impairment, HealthyRecruiting
Est. primary completion 2027-02-01 · NCT07734610 · CT.gov ↗
What to watch
April 2027 (1)
Phase 1Hematological MalignanciesActive not recruiting
Est. primary completion 2027-04-30 · NCT05347225 · CT.gov ↗
What to watch
May 2027 (1)
Phase 3Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-05-19 · NCT05624554 · CT.gov ↗
What to watch
September 2027 (1)
Phase 1/2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-09-17 · NCT03162536 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2027-12-31 · NCT07557056 · CT.gov ↗
What to watch
2029 (6)
January 2029 (1)
Phase 2Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic LeukaemiaRecruiting
Est. primary completion 2029-01-04 · NCT04728893 · CT.gov ↗
What to watch
May 2029 (1)
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2029-05-17 · NCT05458297 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2029-06-01 · NCT06863402 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Waldenstrom MacroglobulinemiaNot yet recruiting
Est. primary completion 2029-08-01 · NCT07464210 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2029-10-20 · NCT07194980 · CT.gov ↗
What to watch
December 2029 (1)
Phase 2Chronic Lymphocytic LeukemiaNot yet recruiting
Est. primary completion 2029-12-01 · NCT07690891 · CT.gov ↗
What to watch
2030 (2)
September 2030 (1)
Phase 2Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma, Marginal Zone Lymphoma …Recruiting
Est. primary completion 2030-09-25 · NCT07583810 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Chronic Lymphocytic LeukemiaNot yet recruiting
Est. primary completion 2030-12-01 · NCT07796373 · CT.gov ↗
What to watch
2031 (1)
July 2031 (1)
Phase 2Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell LymphomaRecruiting
Est. primary completion 2031-07-31 · NCT07673367 · CT.gov ↗
What to watch
2032 (2)
June 2032 (1)
Phase 3Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2032-06-01 · NCT05947851 · CT.gov ↗
What to watch
September 2032 (1)
Phase 3Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2032-09-07 · NCT06136559 · CT.gov ↗
What to watch

See the full readout calendar ↗